Effects of Nitrendipine on Blood Pressure, Renin-Angiotensin-System and Atrial Natriuretic Peptide in Hypertensive Type I Diabetic Patients

Lehnert, Hendrik; Schmitz, H. J.; Preuß, Karlheinz; Küstner, Eva; Krause, U.; Beyer, Jörg

doi:10.1055/s-2007-1002039

Cited by 7 publications

(7 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An increase in PRA after temocapril therapy is expected due to a reduction in circulating angiotensin II levels (15). In some previous reports using sustained-release diltiazem (15) and nitrendipine (16), PRA has been reported to be increased. Our finding that PRA was increased by amlodipine therapy is in accordance with these reports.…”

Section: Ace Inhibitormentioning

confidence: 99%

“…There are three possible mechanisms by which CCBs enhance PRA. First, the increased PRA during CCB treatment could be partly explained by reflex sympathetic activation (16). Second, increased PRA may reflect the direct action of the CCB on renal juxtaglomerular cells.…”

Section: Ace Inhibitormentioning

confidence: 99%

“…Second, increased PRA may reflect the direct action of the CCB on renal juxtaglomerular cells. Since the intracellular calcium concentration has been shown to inversely affect renin secretion, a CCB might thus enhance PRA (16). Third, slight natriuresis by the CCB may cause mild volume loss, resulting in an increase in PRA (15).…”

Section: Ace Inhibitormentioning

confidence: 99%

See 2 more Smart Citations

Differential Effects of a Long-Acting Angiotensin Converting Enzyme Inhibitor (Temocapril) and a Long-Acting Calcium Antagonist (Amlodipine) on Ventricular Ectopic Beats in Older Hypertensive Patients.

Eguchi

Kario²,

Shimada³

2002

Hypertens Res

View full text Add to dashboard Cite

We studied differences in the effects of a long-acting angiotensin-converting enzyme (ACE) inhibitor (temocapril) and a long-acting calcium channel blocker (amlodipine) on ventricular ectopic beats (VEB) in relation to sympathetic nerve activity in 46 patients with essential hypertension. We performed 24-h Holter electrocardiography and ambulatory blood pressure (BP) monitoring simultaneously, and examined blood samples during the baseline, temocapril and amlodipine treatment periods. The ambulatory BP was lower in the amlodipine period than in the temocapril period. However, the number of VEB was significantly increased in the amlodipine period compared to that in the baseline period (11.9 vs. 7.4/day, p 0.05). In the temocapril period, the number of VEB was not significantly increased compared to that in the baseline period (8.6 vs. 7.4/day, p 0.30). Ambulatory heart rate (HR) was significantly increased in the amlodipine

show abstract

Section: Ace Inhibitormentioning

confidence: 99%

Section: Ace Inhibitormentioning

confidence: 99%

See 1 more Smart Citation

Differential Effects of a Long-Acting Angiotensin Converting Enzyme Inhibitor (Temocapril) and a Long-Acting Calcium Antagonist (Amlodipine) on Ventricular Ectopic Beats in Older Hypertensive Patients.

Eguchi

Kario²,

Shimada³

2002

Hypertens Res

View full text Add to dashboard Cite

show abstract

“…These findings also indicate that the increase of ANP plasma levels is not the result of a mechanical overload on the left cardiac chambers but the result of a pharmacological action (12). There are not available references concerning such medium-term studies with verapamil or other phenylalkylamines Studies concerning another category of calcium-entry blockers, the angioselective dihydropyridines arrived to conflictive results (13)(14)(15)(16)(17)(18)(19).…”

Section: Introductionmentioning

confidence: 99%

Atrial natriuretic peptide contributes to the antihypertensive action of many drugs

Papadopoulos

Kokkas

2003

Eur. J. Drug Metab. Pharmacokinet.

View full text Add to dashboard Cite

Data derived from a 10 years research program of our team demonstrate that many categories of antihypertensive drugs like beta-adrenergic blockers, alpha1-adrenergic blockers, ACE inhibitors, AT1-receptor antagonists and calcium-entry blockers increase plasma atrial natriuretic peptide (ANP) levels after a medium-term treatment of patients suffering from moderate essential hypertension. ANP always increases despite the drop of the arterial pressure and the fact that the left atrial and ventricular diameters remain unchanged or slightly reduced. These findings indicate that the increase of ANP plasma levels is not the result of a mechanical overload in the left cardiac chambers but the result of a pharmacological action. In conclusion, ANP is a universal factor contributing to the antihypertensive action of many drugs.

show abstract

“…In man, the basal plasma levels of ANF appear to be increased by acute administration of dihydropyridine calcium channel blockers [18,19,22], and a marked decrease of plasma ANF has been observed during long-term calcium blocker treatment of systemic hypertension [15,17,25]. Rapid ventricular pacing leads to acute stimulation of ANF secretion, which can be almost completely inhibited by pre-treatment with the calcium antagonist verapamil [8].…”

Section: Introductionmentioning

confidence: 99%

The dihydropyridine calcium channel blocker BAY t 7207 attenuates the exercise induced increase in plasma ANF and cyclic GMP in patients with mildly impaired left ventricular function

Kentsch

Müller-Esch

Otter³

et al. 1995

Eur J Clin Pharmacol

View full text Add to dashboard Cite

In man, chronic antihypertensive calcium antagonist treatment improves cardiac function and reduces plasma ANF concentrations. Physical exercise increases cardiac workload and plasma ANF levels. In the present study, we investigated the effects of acute administration of the dihydropyridine calcium antagonist BAY t 7207 (BAY) during bicycle exercise on plasma ANF and plasma cyclic GMP levels, on mean arterial pressure (MAP), heart rate (HR), and on natriuresis and urinary urodilatin excretion. In a randomized, double-blind placebo controlled cross-over trial, 8 patients (age 56.8 +/- 2.5 y) with documented coronary artery disease and mildly impaired left ventricular function (EF 50.0 +/- 1.3%), received oral BAY (20 mg) or placebo. Forty-five minutes after medication, patients underwent a standardised exercise bicycle test in the supine position (6 min 25 W, 6 min 50 W). Before exercise, MAP was lower after BAY (88.8 +/- 4.1 mmHg) than after placebo (95.7 +/- 3.5 mmHg; p = 0.024), and HR was higher after BAY (76.8 +/- 3.5 bpm) than after placebo (69.5 +/- 3.6 bpm; p = 0.049). Plasma ANF tended to be higher after BAY (31.2 +/- 5.6 pg/ml) than after placebo (26.7 +/- 5.0 pg/ml), and plasma cGMP was not different (BAY 3.4 +/- 0.3, placebo 3.8 +/- 0.3 pmol/ml). During exercise, the relative increases in HR (+43%) and MAP (+17%) were identical after BAY and placebo. In contrast, ANF levels during exercise increased by 130 +/- 28% after placebo but only by 36 +/- 11% after BAY (p = 0.011). In parallel, plasma cyclic GMP increased by 61 +/- 13% after placebo and by 20 +/- 8% after BAY (p = 0.013). At the end of exercise, the BAY-induced reduction in plasma cyclic GMP reflected the reduction in diastolic arterial pressure (r = 0.717; p = 0.045). Compared to placebo, BAY treatment increased the fractional excretion rate of sodium from 0.46 +/- 0.11 to 0.90 +/- 0.22% (p = 0.016), without relation to urinary urodilatin excretion. Thus, the calcium antagonist BAY t 7207 attenuated the exercise-induced increase in plasma ANF and cyclic GMP probably due to its vasodilator effect. The relationship between blood pressure and the ANF system during exercise, which parallels findings during chronic antihypertensive treatment, may open a perspective for early evaluation of long-term therapy with calcium channel blockers.

show abstract

Effects of Nitrendipine on Blood Pressure, Renin-Angiotensin-System and Atrial Natriuretic Peptide in Hypertensive Type I Diabetic Patients

Cited by 7 publications

References 20 publications

Differential Effects of a Long-Acting Angiotensin Converting Enzyme Inhibitor (Temocapril) and a Long-Acting Calcium Antagonist (Amlodipine) on Ventricular Ectopic Beats in Older Hypertensive Patients.

Differential Effects of a Long-Acting Angiotensin Converting Enzyme Inhibitor (Temocapril) and a Long-Acting Calcium Antagonist (Amlodipine) on Ventricular Ectopic Beats in Older Hypertensive Patients.

Atrial natriuretic peptide contributes to the antihypertensive action of many drugs

The dihydropyridine calcium channel blocker BAY t 7207 attenuates the exercise induced increase in plasma ANF and cyclic GMP in patients with mildly impaired left ventricular function

Contact Info

Product

Resources

About